ONP-002 — Clinical data readout
Late 2026
The Phase IIa clinical data readout is projected before year-end 2026.Source filing
OGEN biotech catalysts & pipeline
ORAGENICS INC · Data as of 2026-10-25
Upcoming catalysts
ONP-002 — IND submission
Q4 2026
A Phase IIa feasibility trial is currently enrolling at three sites in Australia, and the Company is advancing its Investigational New Drug (IND) application, with submission anticipated in Q4 2026.Source filing